303 related articles for article (PubMed ID: 37313832)
1. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.
Singh D; Khan MA; Siddique HR
Epigenomics; 2023 Apr; 15(8):517-537. PubMed ID: 37313832
[TBL] [Abstract][Full Text] [Related]
2. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y
Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605
[TBL] [Abstract][Full Text] [Related]
4. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R; Zwergel C; Mai A; Valente S
Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
[TBL] [Abstract][Full Text] [Related]
5. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
Katarzyna R; Lucyna B
J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
[TBL] [Abstract][Full Text] [Related]
8. Current paradigms in epigenetic anticancer therapeutics and future challenges.
Singh M; Kumar V; Sehrawat N; Yadav M; Chaudhary M; Upadhyay SK; Kumar S; Sharma V; Kumar S; Dilbaghi N; Sharma AK
Semin Cancer Biol; 2022 Aug; 83():422-440. PubMed ID: 33766649
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation and cancer (review).
Chen QW; Zhu XY; Li YY; Meng ZQ
Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
[TBL] [Abstract][Full Text] [Related]
10. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
Kumar A; Emdad L; Fisher PB; Das SK
Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics of Breast Cancer: Clinical Status of Epi-drugs and Phytochemicals.
Shukla S; Penta D; Mondal P; Meeran SM
Adv Exp Med Biol; 2019; 1152():293-310. PubMed ID: 31456191
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer.
Ghosh A; Himaja A; Biswas S; Kulkarni O; Ghosh B
Mol Pharm; 2023 Dec; 20(12):5981-6009. PubMed ID: 37899551
[TBL] [Abstract][Full Text] [Related]
13. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
14. Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update.
Mondal P; Natesh J; Penta D; Meeran SM
Semin Cancer Biol; 2022 Aug; 83():503-522. PubMed ID: 33309850
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
17. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.
Madkour MM; Ramadan WS; Saleh E; El-Awady R
Ann Med; 2023 Dec; 55(1):2203946. PubMed ID: 37092854
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
